<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Monoclonal antibody 38.13 was raised against the Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo> cell line Daudi and has been previously shown to recognize a globotriaosylceramide (Pk) determinant expressed selectively on Burkitt and a few other B-cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>We report here that 38.13 binds to a subset of <z:mpath ids='MPATH_458'>normal</z:mpath> B lymphocytes in germinal centres of secondary lymphoid follicles as well as to blood vessels </plain></SENT>
<SENT sid="2" pm="."><plain>In malignant populations equivalent to various developmental compartments of the B-cell lineage, only those with a follicular phenotype express the Pk determinant at detectable levels </plain></SENT>
<SENT sid="3" pm="."><plain>The expression of this <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e>-associated antigen, in common with many others, is therefore regulated in concert with cell lineage and maturation status </plain></SENT>
</text></document>